Table 2.
Baseline characteristics of the two subgroups of patients
| Rookies (n = 35) |
Veterans (n = 31) |
p | |
|---|---|---|---|
| Age (years) | 73 ± 6 | 70 ± 14 | 0.20 |
| Weight (kg) | 87 ± 15 | 85 ± 18 | 0.66 |
| BMI (kgm−2) | 30 ± 4 | 29 ± 5 | 0.44 |
| Education, n (%) | |||
| Elementary school | 16 (46) | 10 (32) | 0.18 |
| Inferior middle school | 15 (43) | 9 (29) | 0.21 |
| Superior middle school | 3 (9) | 10 (32) | 0.07 |
| Degree | 1 (3) | 2 (7) | 0.41 |
| Risk factors, n (%) | |||
| Smoking | 31 (89) | 29 (94) | 0.49 |
| Hypertension | 33 (94) | 28 (91) | 0.55 |
| Hyperlipidaemia | 26 (74) | 21 (68) | 0.56 |
| Diabetes | 14 (40) | 11 (36) | 0.71 |
| Chronic kidney disease | 6 (17) | 7 (23) | 0.58 |
| Family history for CVD | 3 (9) | 6 (19) | 0.09 |
| Comorbidities, n (%) | |||
| Coronary heart disease | 16 (45) | 21 (68) | 0.08 |
| Cerebrovascular disease | 7 (20) | 3 (10) | 0.24 |
| Osteoarticular disease | 19 (54) | 19 (61) | 0.58 |
| Rheumatic diseases | 5 (14) | 2 (7) | 0.30 |
| Age-adjusted Charlson Comorbidity Index | 6 ± 2 | 6 ± 2 | 0.88 |
| Pharmacological therapy, n (%) | |||
| Antiplatelet | 30 (86) | 27 (87) | 0.91 |
| Anticoagulant | 5 (14) | 4 (13) | 0.82 |
| Peripheral artery disease | |||
| Disease duration (years) | 5 ± 5 | 5 ± 5 | 0.89 |
| Lower limb revascularization | 10 (28) | 8 (26) | 0.80 |
| Leriche-Fontaine stage 2a | 24 (69) | 24 (77) | 0.57 |
| Leriche-Fontaine stage 2b | 9 (31) | 9 (23) | 0.57 |
| ABI more affected limb | 0.64 ± 0.17 | 0.65 ± 0.20 | 0.76 |
| ABI less affected limb | 0.81 ± 0.18 | 0.90 ± 0.26 | 0.16 |
| Pain-free walking distance (m), entry | 174 ± 77 | 136 ± 74 | 0.13 |
| 6-min walking distance (m), entry | 312 ± 53 | 285 ± 91 | 0.32 |
| Pain-free walking distance (m), Pre | 192 ± 84 | 208 ± 103 | 0.46 |
| 6-min walking distance (m), Pre | 319 ± 57 | 318 ± 102 | 0.98 |
BMI body mass index, CVD cardiovascular disease, ABI Ankle-Brachial Index